-
Product Insights
NewLeft Atrial Appendage Closure Devices Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies
Left Atrial Appendage Closure Devices Pipeline Market Report Overview Left atrial appendage closure device prevents blood flow into the left atrial appendage, preventing blood clotting or pooling. It consists of left atrial appendage implanted occlusion devices and left atrial appendage ligation devices. One unit refers to one left atrial appendage closure device. The left atrial appendage closure devices pipeline market research report provides a comprehensive understanding of the pipeline products along with their comparative analysis at various stages of development....
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – AUR-105 in Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AUR-105 in Leukemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AUR-105 in Leukemia Drug Details: AUR-105 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AUR-101 in Ankylosing Spondylitis (Bekhterev’s Disease)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AUR-101 in Ankylosing Spondylitis (Bekhterev's Disease) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AUR-101 in Ankylosing Spondylitis (Bekhterev's Disease) Drug Details: AUR-101 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AUR-101 in Psoriatic Arthritis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AUR-101 in Psoriatic Arthritis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AUR-101 in Psoriatic Arthritis Drug Details: AUR-101 is under development for the...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – AUR-101 in Plaque Psoriasis (Psoriasis Vulgaris)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AUR-101 in Plaque Psoriasis (Psoriasis Vulgaris) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AUR-101 in Plaque Psoriasis (Psoriasis Vulgaris) Drug Details: AUR-101 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tunlametinib in Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tunlametinib in Melanoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tunlametinib in Melanoma Drug Details: Tunlametinib (HL-085) is under development for the treatment...
-
Product Insights
Ureter Cancer – Drugs In Development, 2023
Global Markets Direct’s, ‘Ureter Cancer - Drugs In Development, 2023’, provides an overview of the Ureter Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Ureter Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Nodal Marginal Zone B-Cell Lymphoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Nodal Marginal Zone B-Cell Lymphoma - Drugs In Development, 2023’, provides an overview of the Nodal Marginal Zone B-Cell Lymphoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Nodal Marginal Zone B-Cell Lymphoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Splenic Marginal Zone B-Cell Lymphoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Splenic Marginal Zone B-Cell Lymphoma - Drugs In Development, 2023’, provides an overview of the Splenic Marginal Zone B-Cell Lymphoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Splenic Marginal Zone B-Cell Lymphoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Psoriatic Arthritis – Drugs In Development, 2023
Global Markets Direct’s, ‘Psoriatic Arthritis - Drugs In Development, 2023’, provides an overview of the Psoriatic Arthritis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Psoriatic Arthritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...